• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790).
  
• Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (PubMed=32567790).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Unspecified (PubMed=11216673; PubMed=21912889).
  

PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0
Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P., Finlay G.J., Holdaway K.M., Baguley B.C.
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.
Eur. J. Cancer 30:1370-1376(1994)

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H
Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
Eur. J. Cancer 31:230-237(1995)

PubMed=11216673; DOI=10.3727/096504001108747620
Parmar J., Marshall E.S., Charters G.A., Holdaway K.M., Shelling A.N., Baguley B.C.
Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines.
Oncol. Res. 12:149-155(2000)

PubMed=20041153; DOI=10.1371/journal.pone.0008461
Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A., Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G., Baguley B.C., Eccles M.R.
A gene expression signature of invasive potential in metastatic melanoma cells.
PLoS ONE 4:E8461-E8461(2009)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)

PubMed=23658559; DOI=10.3389/fgene.2013.00066
Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S., Finlay G.J., Shelling A.N., Baguley B.C.
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Front. Genet. 4:66.1-66.6(2013)

PubMed=23755070; DOI=10.3389/fgene.2013.00097
Kim J.E., Leung E.Y., Baguley B.C., Finlay G.J.
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.
Front. Genet. 4:97.1-97.8(2013)

PubMed=24455489; DOI=10.3389/fonc.2013.00333
D'mello S.A.N., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H.F., Furneaux C.E., During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.
Evidence that GRIN2A mutations in melanoma correlate with decreased survival.
Front. Oncol. 3:333.1-333.9(2014)

PubMed=32567790; DOI=10.1111/pcmr.12908
Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J., Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S., Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: a valuable model for studying the impact of genetic diversity in melanoma.
Pigment Cell Melanoma Res. 34:136-143(2021)